Noxopharm Ltd. (AU:NOX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Limited, an Australian biotech firm listed on ASX (NOX), has released its corporate governance statement and Appendix 4G for the fiscal year 2024, highlighting its dedication to innovation in cancer and inflammation treatments, and its ownership stake in Nyrada Inc, another company specializing in novel therapies. The documents, confirming compliance with corporate governance standards, are available on the company’s website. Noxopharm is known for developing proprietary drugs using two main technology platforms and for enhancing mRNA vaccines.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.